“We are now,” says editor Ray Blanco, “in the early stages of a huge change in how we treat cancer.” He believes that “serious progress” is being made in the   Read More

“Stocks that soar 178 per cent in six months don’t come along every day,” notes editor Chloe Lutts Jensen. But soar Invivo Therapeutics Holdings Corp. (NVIV-OTCBB, $4.22) did, with a   Read More

This advisory is dropping American Express Co. (AXP-NYSE, $75.64) from its “buy” list. Yes, its shares are yelling “charge it!” (they’re up 29 per cent this year) and running ahead   Read More

None of the latest data on U.S. housing starts and retail sales suggest that America’s recovery is slamming the door closed. But there are doubts among some observers about the   Read More